Receptor Tyrosine Kinase-Targeted Cancer Therapy
In the past two decades, several molecular targeted inhibitors have been developed and evaluated clinically to improve the survival of patients with cancer. Molecular targeted inhibitors inhibit the activities of pathogenic tyrosine kinases. Particularly, aberrant receptor tyrosine kinase (RTK) acti...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2018-11-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/19/11/3491 |
| _version_ | 1811236631366074368 |
|---|---|
| author | Toshimitsu Yamaoka Sojiro Kusumoto Koichi Ando Motoi Ohba Tohru Ohmori |
| author_facet | Toshimitsu Yamaoka Sojiro Kusumoto Koichi Ando Motoi Ohba Tohru Ohmori |
| author_sort | Toshimitsu Yamaoka |
| collection | DOAJ |
| description | In the past two decades, several molecular targeted inhibitors have been developed and evaluated clinically to improve the survival of patients with cancer. Molecular targeted inhibitors inhibit the activities of pathogenic tyrosine kinases. Particularly, aberrant receptor tyrosine kinase (RTK) activation is a potential therapeutic target. An increased understanding of genetics, cellular biology and structural biology has led to the development of numerous important therapeutics. Pathogenic RTK mutations, deletions, translocations and amplification/over-expressions have been identified and are currently being examined for their roles in cancers. Therapies targeting RTKs are categorized as small-molecule inhibitors and monoclonal antibodies. Studies are underway to explore abnormalities in 20 types of RTK subfamilies in patients with cancer or other diseases. In this review, we describe representative RTKs important for developing cancer therapeutics and predicting or evaluated resistance mechanisms. |
| first_indexed | 2024-04-12T12:11:12Z |
| format | Article |
| id | doaj.art-5f748c95f7124f3997477a7cee2d5798 |
| institution | Directory Open Access Journal |
| issn | 1422-0067 |
| language | English |
| last_indexed | 2024-04-12T12:11:12Z |
| publishDate | 2018-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-5f748c95f7124f3997477a7cee2d57982022-12-22T03:33:34ZengMDPI AGInternational Journal of Molecular Sciences1422-00672018-11-011911349110.3390/ijms19113491ijms19113491Receptor Tyrosine Kinase-Targeted Cancer TherapyToshimitsu Yamaoka0Sojiro Kusumoto1Koichi Ando2Motoi Ohba3Tohru Ohmori4Advanced Cancer Translational Research Institute (Formerly, Institute of Molecular Oncology), Showa University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8555, JapanDivision of Allergology and Respiratory Medicine, Department of Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8555, JapanDivision of Allergology and Respiratory Medicine, Department of Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8555, JapanAdvanced Cancer Translational Research Institute (Formerly, Institute of Molecular Oncology), Showa University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8555, JapanDivision of Allergology and Respiratory Medicine, Department of Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8555, JapanIn the past two decades, several molecular targeted inhibitors have been developed and evaluated clinically to improve the survival of patients with cancer. Molecular targeted inhibitors inhibit the activities of pathogenic tyrosine kinases. Particularly, aberrant receptor tyrosine kinase (RTK) activation is a potential therapeutic target. An increased understanding of genetics, cellular biology and structural biology has led to the development of numerous important therapeutics. Pathogenic RTK mutations, deletions, translocations and amplification/over-expressions have been identified and are currently being examined for their roles in cancers. Therapies targeting RTKs are categorized as small-molecule inhibitors and monoclonal antibodies. Studies are underway to explore abnormalities in 20 types of RTK subfamilies in patients with cancer or other diseases. In this review, we describe representative RTKs important for developing cancer therapeutics and predicting or evaluated resistance mechanisms.https://www.mdpi.com/1422-0067/19/11/3491receptor tyrosine kinasemolecular target inhibitorsresistance mechanisms |
| spellingShingle | Toshimitsu Yamaoka Sojiro Kusumoto Koichi Ando Motoi Ohba Tohru Ohmori Receptor Tyrosine Kinase-Targeted Cancer Therapy International Journal of Molecular Sciences receptor tyrosine kinase molecular target inhibitors resistance mechanisms |
| title | Receptor Tyrosine Kinase-Targeted Cancer Therapy |
| title_full | Receptor Tyrosine Kinase-Targeted Cancer Therapy |
| title_fullStr | Receptor Tyrosine Kinase-Targeted Cancer Therapy |
| title_full_unstemmed | Receptor Tyrosine Kinase-Targeted Cancer Therapy |
| title_short | Receptor Tyrosine Kinase-Targeted Cancer Therapy |
| title_sort | receptor tyrosine kinase targeted cancer therapy |
| topic | receptor tyrosine kinase molecular target inhibitors resistance mechanisms |
| url | https://www.mdpi.com/1422-0067/19/11/3491 |
| work_keys_str_mv | AT toshimitsuyamaoka receptortyrosinekinasetargetedcancertherapy AT sojirokusumoto receptortyrosinekinasetargetedcancertherapy AT koichiando receptortyrosinekinasetargetedcancertherapy AT motoiohba receptortyrosinekinasetargetedcancertherapy AT tohruohmori receptortyrosinekinasetargetedcancertherapy |